Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas

NCT02209428 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT02209428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02209428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas
Lead sponsor
Huashan Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2014
Completion date
May 31, 2019
Enrollment
54 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, oligoastrocytoma, oligodendroglioma